Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy the field has pegged as the best bet for attacking the disease.

On Monday, Boehringer Ingelheim GmbH (Ingelheim, Germany) said it is licensing a preclinical fusion protein from Yuhan Corp. (KSE:000100) that activates both GLP-1R and FGF21R. Yuhan will receive $40 million in upfront and near-term payments, and is eligible for up to $830 million in milestones, plus tiered royalties...